# US 2026/0285914 A1 · Antibacterials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0285914 A1
- Document ID: US20260285914A1
- Status: Published application
- Kind: A1
- Application number: 18/874,412
- Filed: 2023-06-13
- Published: 2026-09-24
- Earliest claimed: 2022-06-14
- Assignees: Oxford University Innovation Limited
- Applicants: Oxford University Innovation Limited
- Inventors: Nicholas G. Housden; Colin Kleanthous
- Web page: https://patentgrep.com/patent/US20260285914A1

## CPC

- C07K 14/245: Escherichia (G)
- C07K 14/26: Klebsiella (G)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/70: containing domain for protein-protein interaction
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to antibacterial protein complexes derived from nuclease bacteriocins, and to their production and use, and to related products having an antibacterial surface. The complexes comprise a nuclease bacteriocin polypeptide and an immunity polypeptide linked to a bacteria binding moiety.

## Claims

### Claim 1

An antibacterial protein complex comprising (i) a nuclease bacteriocin polypeptide, and (ii) an immunity polypeptide linked to a bacteria binding moiety, wherein the nuclease bacteriocin polypeptide comprises a translocation domain and a nuclease domain, or a translocation domain, a receptor binding domain and a nuclease domain; and wherein the bacteria binding moiety binds to a ligand on the surface of a Gram-negative bacteria.

### Claim 2 (depends on 1)

The antibacterial protein complex according to claim 1, wherein the bacteria binding moiety is a receptor binding domain of a bacteriocin.

### Claim 3 (depends on 1, 2)

The antibacterial protein complex according to claim 1 or claim 2, wherein the receptor binding domain of the nuclease bacteriocin and the receptor binding domain linked to the immunity polypeptide are different and/or wherein the receptor binding domain of the nuclease bacteriocin and the bacteria binding moiety bind to different Gram-negative bacteria surface ligands and/or different Gram-negative bacterial strains.

### Claim 4 (depends on 1, 2, 3)

The antibacterial protein complex according to any one of claims 1 to 3, wherein the immunity polypeptide is linked to multiple bacteria targeting moieties or to multiple bacteriocin receptor binding domains, optionally wherein each bacteria binding moiety binds to a different bacterial surface ligand and/or different bacterial strain, and/or wherein each bacteria binding moiety binds to a different ligand and/or bacterial strain than the receptor binding domain of the nuclease bacteriocin polypeptide.

### Claim 5 (depends on 1, 2, 3, 4)

The antibacterial protein complex according to any one of claims 1 to 4, wherein the bacteria binding moiety linked to the immunity polypeptide is a nanobody.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibacterial protein complex according to any one of claims 1 to 5, wherein the immunity polypeptide is linked to an M-type bacteriocin.

### Claim 7 (depends on 6)

The antibacterial protein complex according to claim 6, wherein the M-type bacteriocin is KvarM.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

An antibacterial composition comprising the antibacterial protein complex according to any one of claims 1 to 7.

### Claim 9 (depends on 8)

The composition of claim 8, that is a pharmaceutical composition.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 9)

The antibacterial protein complex according to any one of claims 1 to 7, or the pharmaceutical composition of claim 9, for use in a method for treatment of a human or animal body by therapy.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 9)

The antibacterial protein complex according to any one of claims 1 to 7, or the pharmaceutical composition of claim 9, for use in a method for treating or preventing a bacterial infection.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 9)

A method of treating a subject, the method comprising administering an antibacterial protein complex according to any one of claims 1 to 7 or the pharmaceutical composition of claim 9, to the subject.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the method is for treating or preventing a bacterial infection.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7)

A medical device comprising the antibacterial protein complex according to any one of claims 1 to 7.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7)

One or more polynucleotides encoding the antibacterial protein complex according to any one of claims 1 to 7.

### Claim 16 (depends on 15)

One or more vectors comprising the polynucleotide or polynucleotides of claim 15.

### Claim 17 (depends on 16)

A host cell comprising the vector or vectors of claim 16.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 17)

A method for producing an antibacterial protein complex according to any one of claims 1 to 7, the method comprising culturing the host cell of claim 17 and isolating the antibacterial protein complex from the culture.

### Claim 19

A product having an antibacterial surface, wherein the surface comprises an antibacterial protein complex comprising an immunity polypeptide and protein bacteriocin nuclease.

### Claim 20

A method of providing a product with an antibacterial surface, the method comprising:
(I)
(a) providing an antibacterial protein complex comprising an immunity polypeptide and protein bacteriocin nuclease; and
(b) binding the antibacterial protein complex to the surface of the product; or
(II)
(a) binding an immunity polypeptide to the surface of the product; and
(b) binding a protein nuclease bacteriocin to the surface-bound immunity protein.

### Claim 21 (depends on 19, 20)

The product according to claim 19 or the method according to claim 20, wherein the immunity polypeptide is linked to a bacteria binding moiety that binds to a ligand on the surface of a bacteria.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 21)

The product according to claim 21, wherein the antibacterial protein complex is that of any one of claims 1 to 7.
